ORPHA:79480
Pemphigus erythematosus
Also known as: Seborrheic pemphigus · Senear-Usher syndrome
Publications
515
64.8th percentile
Trials
0
Interventional, condition-specific
Researchers
795
Distinct authors in sample
Gene link
—
Readiness
3/6
Stages with a signal
Clinical definition (Orphanet)
A rare superficial pemphigus disease characterized clinically by well-demarcated, localized, erythematous, scaly, hyperkeratotic, crusted plaques, with frequent butterfly distribution over the malar area of the face (but also commonly involving trunk and scalp, and less frequently the extremities, with a photoexposed distribution). Histologically, granular deposits along the dermal-epidermal junction, in addition to intercellular deposition in the upper epidermis, are observed.
How rare: How common this is has not been clearly measured.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0019323
- UMLS:C0263312
Additional Mondo synonyms (1)
seborrheic pemphigus
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
3/6 stages with a signal
No specific-condition interventional trial, but broader-category trials exist — discuss eligibility with a clinician.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
515 matched papers (163 in last 10 years) Source
- Phenotype characterisedPresent
14 HPO annotations (e.g. Localized skin lesion; Malar rash; Erythematous plaque) Source
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialPartial
None under the specific name; 56 for broader category pemphigus
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
14
Associated phenotypes · MONDO:0019323
- Localized skin lesion
- Malar rash
- Erythematous plaque
- Antinuclear antibody positivity
- Abnormal blistering of the skin
Showing 5 of 14 — open Monarch for the full list.
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
No drugs or clinical candidates returned for this Mondo ID on Open Targets.
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
515
515 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
515 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
163 in the last 10 years · high confidence · 64.8th percentile (publications denominator)
Phrase hits: 515 · MeSH hits: 0
Who's working on it?
795
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Howard MS11 papers · 2025
Georgia Dermatopathology Associates, Atlanta, GA 30307-1000, USA. mhoward@gadermpath.com
Papers in Europe PMC - 02Hashimoto T7 papers · 2025
Institute of Cutaneous Cell Biology, Kurume University, Fukuoka, Japan.
Papers in Europe PMC - 03Abreu-Velez AM6 papers · 2019
Georgia Dermatopathology Associates, Atlanta, Georgia, USA.
Papers in Europe PMC - 04Abréu-Vélez AM4 papers · 2025
Institute for Molecular Medicine and Genetics, Medical College of Georgia, CB 2803, 1120 15th Street, GA 30912-2630, Augusta, USA, aavelez@mail.mcg.edu
Papers in Europe PMC - 05Murrell DF4 papers · 2021
Department of Dermatology, St George Hospital, University of New South Wales, Sydney, Australia.
Papers in Europe PMC - 06Abreu Velez AM3 papers · 2025
Georgia Dermatopathology Associates, Atlanta, GA, USA. abreuvelez@yahoo.com
Papers in Europe PMC - 07Bollag WB3 papers · 2004Papers in Europe PMC
- 08Chanprapaph K3 papers · 2025
Division of Dermatology, Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
Papers in Europe PMC - 09Chen X3 papers · 2024
Department of Dermatology, Peking University First Hospital, 8 Xishiku Street, Xicheng District, Beijing, 100034, China.
Papers in Europe PMC - 10Lehman JS3 papers · 2021
Department of Dermatology, Mayo Clinic, Rochester, Minnesota; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present). 56 trials are registered for pemphigus, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 11 September 2026 · last trial check 11 September 2026
No matched interventional trials. This is true for 77.2% of diseases in the trials denominator (5501 of 7126). Here are the researchers publishing on it.
high confidence · 38.6th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
56 interventional trials matched pemphigus, the broader category — listed below. Those studies are not counted in the condition-specific total.
Broader category: pemphigus
56
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT07769333·NOT YET RECRUITING·Rituximab With Corticosteroids Versus Corticosteroids Plus Azathioprine for Moderate-to-Severe Pemphigus Vulgaris
Conditions: Pemphigus Vulgaris · Rituximab (RTx)·Matched via name phrase
- NCT06454357·RECRUITING·A Clinical Study of B007 in the Treatment of Pemphigus.
Conditions: Pemphigus·Matched via name phrase
- NCT06663943·NOT YET RECRUITING·A Randomized Study on Pemphigus Treatment With Humanized CD38 Antibody CM313.
Conditions: Pemphigus Disease · Pemphigus Vulgaris (PV)·Matched via name phrase
- NCT04422912·RECRUITING·A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)
Conditions: Pemphigus Vulgaris·Matched via name phrase
- NCT06581562·RECRUITING·Open-label Single-Center Study to Evaluate the Safety and Efficacy of Combining Rituximab and AB-101 in B-cell Associated Autoimmune Diseases.
Conditions: Rheumatoid Arthritis · Pemphigus Vulgaris · Granulomatosis With Polyangiitis · Systemic Lupus Erythematosus·Matched via name phrase
- NCT05898308·RECRUITING·Comparison of a Personalized Maintenance Therapy With the Standard Treatment in Pemphigus
Conditions: Pemphigus · Dermatologic Disease·Matched via name phrase
- NCT07681388·RECRUITING·CD19 CAR-T Therapy for Refractory Pemphigus Vulgaris
Conditions: Pemphigus Vulgaris·Matched via name phrase
- NCT07641725·RECRUITING·Comparison of the Efficacy of Clobetasol Propionate 0.05% Mouthwash, Photobiomodulation, and Their Combination in Managing of Oral Lesions in Patient With Pemphigus Vulgaris.
Conditions: Oral Lesions in Patients With Pemphigus Vulgaris·Matched via name phrase
- NCT06904040·NOT YET RECRUITING·A Single-center Study of CM313 in Patients With Pemphigus
Conditions: Pemphigus·Matched via name phrase
- NCT06971172·NOT YET RECRUITING·Low-level Laser Therapy on Oral Pemphigus Vulgaris Patients.
Conditions: Pemphigus Vulgaris·Matched via name phrase
- NCT06901427·NOT YET RECRUITING·Impact of a Lifestyle Program on Quality of Life in Pemphigus Patients
Conditions: Pemphigus Disease·Matched via name phrase
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 0 · after dedupe 0 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 0 · dropped 0 · fetched 2026-07-30
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Pemphigus erythematosus — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Pemphigus erythematosus" OR "Seborrheic pemphigus" OR "Senear-Usher syndrome"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Pemphigus erythematosus" OR "Seborrheic pemphigus" OR "Senear-Usher syndrome"
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"pemphigus"
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T02:28:36.425Z
